3 results
STUDY OBJECTIVESPrimary objectiveTo assess the safety, tolerability and local tolerance of two different intravenous infusion doses over 72 hours of a new dosing regimen and a new formulation of MCI-186 in subjects with acute ischemic stroke.…
Primary:To determine the degree pain relief 6 months after THA/TKA when screened pre-operative for centralized pain and subsequent treated accordingly for a period of 10 weeks with Duloxetine compared to usual care (no Duloxetine) Secondary:To…
The primary objective of the trial is to determine if ischemic stroke subjects with a baseline NIH Stroke Scale Score (NIHSSS] >= 10 (8-9 with positive CTA) treated with recombinant tissue plasminogen activator (rt-PA; [Alteplase recombinant…